Cystic Fibrosis Foundation Holds 4.55M Shares in BiomX Inc.
Ticker: PHGE · Form: SC 13G/A · Filed: Jan 30, 2024 · CIK: 1739174
| Field | Detail |
|---|---|
| Company | Biomx Inc. (PHGE) |
| Form Type | SC 13G/A |
| Filed Date | Jan 30, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | bullish |
Complexity: simple
Sentiment: bullish
Topics: institutional-ownership, amendment, biotechnology, non-profit-investment
TL;DR
**Cystic Fibrosis Foundation owns 4.55M BiomX shares, signaling continued interest.**
AI Summary
The Cystic Fibrosis Foundation, a Delaware-based organization, filed an amended SC 13G/A on January 30, 2024, disclosing its beneficial ownership in BiomX Inc. The Foundation now holds 4,552,315 shares of BiomX Common Stock, representing a significant stake. This matters to investors because it indicates a major non-profit organization with a direct interest in cystic fibrosis research maintains a substantial investment in BiomX, a company developing biological products, potentially signaling confidence in its long-term prospects related to the disease.
Why It Matters
This filing shows a key non-profit organization, the Cystic Fibrosis Foundation, has a substantial stake in BiomX, which could imply a vote of confidence in the company's work related to cystic fibrosis.
Risk Assessment
Risk Level: low — This filing is an amendment to a previous disclosure and indicates a stable, significant ownership by a non-profit, generally not a high-risk event.
Analyst Insight
A smart investor would view this as a positive signal, suggesting that a key non-profit with deep knowledge in the disease area has confidence in BiomX's potential, warranting further research into BiomX's pipeline and financial health.
Key Numbers
- 4,552,315 — Shares Beneficially Owned (This is the total number of BiomX Inc. common stock shares held by the Cystic Fibrosis Foundation, indicating their significant investment.)
- $0.0001 — Par Value Per Share (This is the nominal value of each share of BiomX Inc. Common Stock.)
Key Players & Entities
- Cystic Fibrosis Foundation (company) — reporting person and beneficial owner of BiomX Inc. shares
- BiomX Inc. (company) — the issuer of the securities being reported
- Delaware (company) — place of organization for Cystic Fibrosis Foundation
- 4,552,315 (dollar_amount) — number of shares beneficially owned by Cystic Fibrosis Foundation
- January 30, 2024 (date) — date of event requiring the filing of this statement
Forward-Looking Statements
- The Cystic Fibrosis Foundation will maintain its significant stake in BiomX Inc. for the foreseeable future. (Cystic Fibrosis Foundation) — medium confidence, target: 2025-01-30
- BiomX Inc. will continue to receive attention and potential support from organizations focused on cystic fibrosis research. (BiomX Inc.) — high confidence, target: 2025-01-30
FAQ
Who is the reporting person in this SC 13G/A filing?
The reporting person in this SC 13G/A filing is the Cystic Fibrosis Foundation, as stated under 'Names of Reporting Persons' on the cover page.
What is the name of the issuer whose securities are being reported?
The issuer of the securities being reported is BiomX Inc., as identified under 'Name of Issuer' on the cover page of the filing.
How many shares of BiomX Inc. Common Stock does the Cystic Fibrosis Foundation beneficially own?
The Cystic Fibrosis Foundation beneficially owns 4,552,315 shares of BiomX Inc. Common Stock, as detailed in item 5, 'Sole Voting Power', on the cover page.
What is the CUSIP number for the class of securities reported?
The CUSIP number for the Common Stock, $0.0001 par value per share, of BiomX Inc. is 09090D103, as stated on the cover page.
When was the date of the event which required the filing of this statement?
The date of the event which required the filing of this statement was January 30, 2024, as indicated on the cover page.
Filing Stats: 1,018 words · 4 min read · ~3 pages · Grade level 8.7 · Accepted 2024-01-30 16:05:52
Key Financial Figures
- $0.0001 — Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class o
Filing Documents
- d744616dsc13ga.htm (SC 13G/A) — 49KB
- 0001193125-24-019410.txt ( ) — 51KB
SIGNATURES
SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: January 30, 2024 By: /s/ Ania Howell Name: Ania Howell Title: Vice President, Financial Services